全文获取类型
收费全文 | 3733篇 |
免费 | 231篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 63篇 |
妇产科学 | 54篇 |
基础医学 | 419篇 |
口腔科学 | 38篇 |
临床医学 | 273篇 |
内科学 | 718篇 |
皮肤病学 | 44篇 |
神经病学 | 213篇 |
特种医学 | 19篇 |
外国民族医学 | 1篇 |
外科学 | 213篇 |
综合类 | 359篇 |
现状与发展 | 1篇 |
预防医学 | 228篇 |
眼科学 | 74篇 |
药学 | 940篇 |
1篇 | |
中国医学 | 133篇 |
肿瘤学 | 288篇 |
出版年
2024年 | 3篇 |
2023年 | 23篇 |
2022年 | 43篇 |
2021年 | 79篇 |
2020年 | 68篇 |
2019年 | 76篇 |
2018年 | 68篇 |
2017年 | 85篇 |
2016年 | 116篇 |
2015年 | 99篇 |
2014年 | 202篇 |
2013年 | 321篇 |
2012年 | 236篇 |
2011年 | 244篇 |
2010年 | 197篇 |
2009年 | 186篇 |
2008年 | 231篇 |
2007年 | 209篇 |
2006年 | 205篇 |
2005年 | 166篇 |
2004年 | 161篇 |
2003年 | 146篇 |
2002年 | 95篇 |
2001年 | 83篇 |
2000年 | 60篇 |
1999年 | 64篇 |
1998年 | 59篇 |
1997年 | 51篇 |
1996年 | 41篇 |
1995年 | 39篇 |
1994年 | 34篇 |
1993年 | 54篇 |
1992年 | 27篇 |
1991年 | 33篇 |
1990年 | 40篇 |
1989年 | 30篇 |
1988年 | 27篇 |
1987年 | 25篇 |
1986年 | 17篇 |
1985年 | 32篇 |
1984年 | 25篇 |
1983年 | 19篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1979年 | 9篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 6篇 |
1975年 | 4篇 |
排序方式: 共有4085条查询结果,搜索用时 10 毫秒
81.
《International journal of urology》2017,24(7):525-531
82.
83.
Sickle cell disease (SCD) is relatively mild among Kuwaiti Arabs. However, an atypical subset of patients exists with frequent, severe vaso-occlusive crisis and osteonecrosis. The thermolabile variant of MTHFR, resulting from a C-->T mutation at nucleotide 677, has been shown to be associated with hyperhomocysteinemia, which is an important risk factor for premature vascular disease. We have screened an unselected group of 41 Kuwaiti SCD patients (33 SS and 8 Sbeta(0)-thal) attending the Hematology Clinic of Kuwait University Teaching Hospital for the MTHFR mutation, using a PCR-RFLP method. The patients were aged 2-41 years (mean of 12.8 +/- 8.6). One (2.4%) individual was homozygous for the mutation while 15 (36.6%) were heterozygous, giving an allele frequency of 20.7%. Twenty-one patients (14 SS and 7 Sbeta(0)-thal) were screened for osteonecrosis using MRI of the hip (spin-echo T1- and T2-weighted images). Seven (33.3%) had varying degrees of osteonecrosis, among whom the frequency of the 677 C-->T allele was 21.4%. The frequency was identical among those without osteonecrosis. Although the allele frequency is higher among our patients compared to American SS patients, our results do not suggest an association with osteonecrosis. 相似文献
84.
同型半胱氨酸及其相关酶基因多态性与糖尿病周围神经病变的关系 总被引:7,自引:0,他引:7
研究对象为 2型糖尿病 (DM )有周围神经病变组 (60例 )、2型DM无周围神经病变组 (4 6例 )和正常对照组 (5 0例 )。分别测定 3组血浆同型半胱氨酸 (Hcy) ,血清叶酸、维生素B12 水平及Hcy代谢关键酶亚甲基四氢叶酸还原酶 (MTHFR)的基因型。结果显示 ,高Hcy及低叶酸、维生素B12 水平与 2型DM患者伴发周围神经病变相关 ,而MTHFR的基因多态性只与DM有关而与DM周围神经病变无相关性。 相似文献
85.
Rongqiang Liu Shiyang Zheng Cui yan Yang Yajie Yu Shengjia Peng Qianmin Ge Qi Lin Qiuyu Li Wenqing Shi Yi Shao 《Medicine》2021,100(14)
Background:Numbers of studies have reported that the expression of aldo-keto reductase family 1 member B10 (AKR1B10) is abnormal in digestive system cancers, and could be used as a prognostic biomarker. However, the results are argued. Therefore, we conduct a meta-analysis to comprehensively evaluate the prognostic value of high AKR1B10 expression for overall survival (OS), disease specific survival (DSS), and disease-free survival/recurrence-free survival (DFS/PFS) in digestive system cancers.Methods:Hazard ratios (HRs) with its 95% confidence intervals (CIs) were calculated to assess the prognostic value of AKR1B10 by using the random effects model. The STATA version 12.0 software were used to perform all the analyses.Results:Eleven articles including 1428 patients involved in this meta-analysis. The pooled analysis suggested that high AKR1B10 expression was not associated with OS (HR: 1.18; 95% CI: 0.69–2.00) and DFS/PFS (HR: 1.08, 95% CI: 0.67–1.76) in digestive system cancers. However, Further analysis revealed that high AKR1B10 expression indicated poor OS in oral squamous cell carcinomas (OSCC) (HR: 2.92, 95% CI: 1.86–4.58) and favorable DSS in hepatocellular carcinoma (HCC) (HR: 0.71, 95% CI: 0.52–0.97).Conclusions:The prognostic value of high AKR1B10 expression varied in different types of digestive system cancers. Further studies exploring the prognostic role of AKR1B10 in digestive system cancers are needed. 相似文献
86.
Summary Aldose reductase inhibitors (ARIs) attenuate diabetic complications in several tissues, including lens, retina, kidney, blood
vessels, striated muscle and peripheral nerve. However, it is unclear whether their action in diabetes mellitus depends directly
on inhibiting the conversion of glucose to sorbitol by aldose reductase or indirectly by reducing the sorbitol available for
subsequent metabolism to fructose by sorbitol dehydrogenase. To identify the polyol pathway step most relevant to complications,
particularly neuropathy, we compared the biochemical effects of a sorbitol dehydrogenase inhibitor, WAY-135 706, (250 mg ·
kg−1· day−1) and an ARI, WAY-121 509, (10 mg · kg−1· day−1) on a variety of tissues, and their effects on nerve perfusion and conduction velocity. After 6 weeks of untreated streptozotocin
diabetes, rats were treated for 2 weeks. Sorbitol was elevated 2.1–32.6-fold by diabetes in lens, retina, kidney, aorta, diaphragm,
erythrocytes and sciatic nerve; this was further increased (1.6–8.2-fold) by WAY-135 706 whereas WAY-121 509 caused a marked
reduction. Fructose 1.6–8.0-fold elevated by diabetes in tissues other than diaphragm, was reduced by WAY-135 706 and WAY-121
509, except in the kidney. Motor and sensory nerve conduction velocities were decreased by 20.2 and 13.9 %, respectively with
diabetes. These deficits were corrected by WAY-121 509, but WAY-135 706 was completely ineffective. A 48.6 % diabetes-induced
deficit in sciatic nutritive endoneurial blood flow was corrected by WAY-121 509, but was unaltered by WAY-135 706. Thus,
despite profound sorbitol dehydrogenase inhibition, WAY-135 706 had no beneficial effect on nerve function. The data demonstrate
that aldose reductase activity, the first step in the polyol pathway, makes a markedly greater contribution to the aetiology
of diabetic neurovascular and neurological dysfunction than does the second step involving sorbitol dehydrogenase. [Diabetologia
(1997) 40: 271–281]
Received: 13 August 1996 and in final revised form: 6 December 1996 相似文献
87.
Akira Honda Tadashi Yoshida Naomi Tanaka Yasushi Matsuzaki Bingfang He Toshiaki Osuga M.D. Nobuaki Kobayashi Kazue Ozawa 《Journal of gastroenterology》1993,28(3):406-414
In Japan the composition of gallstones is changing rapidly from the once-predominant brownpigment stones to cholesterol ones.
The present work was undertaken to clarify the mechanism of cholesterol supersaturated bile production in Japanese patients
with cholesterol gallstones. In 26 non-obese and normolipidemic patients (11 with cholesterol gallstones, 8 with black- or
brown-pigment gallstones, 7 without gallstones) a liver biopsy and hepatic bile were surgically obtained under standardized
conditions. The cholesterol saturation of hepatic bile was significantly higher in cholesterol gallstone patients than in
gallstone-free controls (195 ±10 vs. 146 ±8%, respectively; P < 0.01). The microsomal activities of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme for cholesterol synthesis, cholesterol 7 α-hydroxylase, the rate-limiting
enzyme for bile acid synthesis, and 7 α-hydroxy-4-cholesten-3-one 12 α-hydroxylase (12 α-hydroxylase), the rate-limiting enzyme
for cholic acid synthesis, were assayed simultaneously in the same subjects. There were positive correlations between HMG-CoA
reductase and cholesterol 7 α-hydroxylase activities (Rs = 0.62, P < 0.005), and between cholesterol 7 α-hydroxylase and 12
α-hydroxylase activities (Rs = 0.44, P < 0.05) in all subjects, irrespective of the existence of gallstones. The activities
of the three rate-limiting enzymes did not differ significantly among the three groups (cholesterol stone, pigment stone and
stone-free). In conclusion, the cholesterol supersaturation of hepatic bile in nonobese and normolipidemic Japanese patients
with cholesterol gallstones does not result from an increased hepatic cholesterol synthesis or a decreased bile acid synthesis.
This study was supported in part by a Grant-in-Aid for Scientific Research (No. 02454226) from the Ministry of Education,
Science and Culture of Japan, and a grant from University of Tsukuba Project Research. 相似文献
88.
A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. 总被引:2,自引:0,他引:2
The effects of the aldose reductase inhibitor ponalrestat (600 mg day-1) on sensory, electrophysiological, and autonomic function were examined in 50 patients with chronic symptomatic, distal symmetrical diabetic neuropathy in a 52-week randomized, double-blind, parallel-group, placebo-controlled, single-centre study. In an endeavour to identify patients with a degree of neuropathy potentially amenable to pharmacological intervention, a minimum conduction velocity of 30 m s-1 was set for the peroneal motor nerve. At 52 weeks, no significant differences were observed between the ponalrestat and placebo groups in motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic R-R interval variability on deep breathing and orthostatic blood pressure response). Ponalrestat was clinically well tolerated and had no significant effect on glycaemic control. The lack of beneficial effects of ponalrestat may in part reflect the advanced stage of the neuropathic process in patients with established symptomatic disease, and the poor reproducibility of current neurophysiological techniques. Firmer knowledge of clinico-pathological correlates allied to improved non-invasive neurophysiological measurement techniques should facilitate the selection of patients for future therapeutic trials in diabetic neuropathy. 相似文献
89.
Suzanne Schol‐Gelok Tom van der Hulle Joseph S. Biedermann Teun van Gelder Frederikus A. Klok Liselotte M. van der Pol Jorie Versmissen Menno V. Huisman Marieke J. H. A. Kruip 《European journal of clinical investigation》2018,48(7)
Background
Acute pulmonary embolism may be ruled out by combining nonhigh clinical probability and a normal D‐dimer level. Both antiplatelet drugs and HMG‐CoA reductase inhibitors (statins) have been associated with effects on thrombus formation, potentially influencing D‐dimer levels in this setting, leading to a higher rate of false‐negative tests. Therefore, we determined whether D‐dimer levels in patients with suspected pulmonary embolism are affected by concomitant use of antiplatelet drugs and/or statins and evaluated whether the effect of antiplatelet drugs or statins might affect diagnostic accuracy.Materials and methods
We performed a posthoc analysis in the YEARS diagnostic study, comparing age‐ and sex‐adjusted D‐dimer levels among users of antiplatelet drugs, statins and nonusers. We then reclassified patients within the YEARS algorithm by developing a model in which we adjusted D‐dimer cut‐offs for statin use and evaluated diagnostic accuracy.Results
We included 156 statins users, 147 antiplatelet drugs users and 726 nonusers of either drugs, all with suspected pulmonary embolism . Use of antiplatelet drugs did not have a significant effect, whereas statin use was associated with 15% decrease in D‐dimer levels (95% CI, ?28% to ?0.6%). An algorithm with lower D‐dimer thresholds in statin users yielded lower specificity (0.42 compared to 0.33) with no difference in false‐negative tests.Conclusions
We conclude that use of statins but not of antiplatelet agents is associated with a modest decrease in D‐dimer levels. Adjusting D‐dimer cut‐offs for statin use did, however, not result in a safer diagnostic strategy in our cohort.90.
Background: Cardiovascular complications are strongly correlated with a higher risk of mortality during follow-up after noncardiac surgery. However, controversy remains regarding whether perioperative administration of hydroxymethylglutaryl-CoA reductase inhibitors (statins) has a beneficial effect on patient outcomes.Objective: We performed a meta-analysis to validate the hypothesis that perioperative statins improve patient outcomes after noncardiac surgery.Methods: Electronic databases (PubMed, Web of Science, EMBASE, and the Cochrane Library) were searched for randomized controlled trials (RCTs) published up to 10 November 2017. RCTs were eligible for inclusion if they compared perioperative statin treatment with control treatment in patients scheduled for noncardiac surgery and reported data pertaining to clinical outcomes.Results: Twelve RCTs involving 4707 patients (2371 in the perioperative statin group and 2336 in the control group) were ultimately included in this meta-analysis. The incidences of postoperative myocardial infarction, composite of death/myocardial infarction/stroke and new cases of atrial fibrillation were all lower in patients treated with statins than in control group patients, as shown by the fixed-effects model (odds ratio (OR)?=?0.460, 95% confidence interval (CI)?=?0.324–0.653, p?=?0 for myocardial infarction; OR?=?0.617, 95% CI?=?0.476–0.801, p?=?0 for composite of death/myocardial infarction/stroke; OR?=?0.406, 95% CI?=?0.247–0.666, p?=?0 for new atrial fibrillation). No significant differences in the incidences of stroke or transient ischemic attack, all-cause mortality and cardiovascular mortality were observed between the statin and control arms.Conclusions: This meta-analysis supports the hypothesis that perioperative statins effectively reduce the incidences of postoperative myocardial infarction, composite of death/myocardial infarction/stroke and new cases of atrial fibrillation in patients undergoing noncardiac surgery.
- Key Messages
Cardiovascular complications are strongly correlated with a higher risk of mortality during follow-up after noncardiac surgery.
We performed a meta-analysis to confirm the hypothesis that perioperative statins improve patient outcomes after noncardiac surgery.